Boston Pharmaceuticals

This study is testing an investigational drug called efimosfermin in people with advanced liver scarring (cirrhosis) caused by a serious fatty liver disease known as MASH. The main goals are to see if the drug is safe and well-tolerated, and to gather early signs of whether it mi…